13
Views
50
CrossRef citations to date
0
Altmetric
Research Article

Fatal Hepatic Failure After Emergence of the Hepatitis B Virus Mutant During Lamivudine Therapy in a Patient with Liver Cirrhosis

Pages 366-369 | Published online: 08 Jul 2009

  • Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC.Inhibition of the replication of hepatitis B virus in vitro by 2',3' dideoxy-3' thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-9.
  • Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M.A preliminary trial of lamivudine of chronic hepatitis B infection. N Engl J Med 1995;113:1258-63.
  • Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B.N Engl J Med 1998;339:61-8.
  • Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine in Asian patients with chronic heptitis B. Gastroenterology 2000;119:172-80.
  • Villeneuve JP, Condeay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatmet for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.
  • Yao FY, Bass, NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000;33:301-7.
  • Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, et al. Beneficial effects of lamivudine in hepatitis B virusrelated decompensated cirrhosis. J Hepatol 2000;33:308-12.
  • Kitay-Cohen Y, Ben-Ari Z, Tur-Kaspa R, Fainguelernt H, Lishner M. Extension of transplantation free time by lamivudine in patients with hepatitis B- induced decompensated cirrhosis. Transplantation 2000;69:2382-3.
  • Liang R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
  • Honkoop P, Niesters HGM, De Man RA, Osterhaus ADME, Schalm SW, Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns. J Hepatol 1997;26:1393-5.
  • Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
  • Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtype. J Gen Virol 1988;69:2575-83.
  • Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Three-year lamivudine therapy in chronic HBV [Abstract]. J Hepatol 1999;30 Suppl 1:59.
  • Chang TT, Lai, CL, Liaw YF, Guan R, Lim SG, Lee CM, et al. Incremental increase in HBeAg seroconversion and continued ALT normalization in Asian Chronic HBV patients treated with lamivudine for four years, Anitiviral Ther 2000;5 Suppl 1:44.
  • Melegari, M, Seaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC an famciclovir administration are replication defective. Hepatology 1998;27:628-33.
  • Ogata N, Fujii K, Takigawa S, Nomota M, Ichida T, Asalura H, Noval patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 1999;59:270-6.
  • Kobayashi, S, Ide T, Sata M. Detection of YMDD Motif Mutations in some lamivudine-untreated asymptomatic hepatitis B virus carries. J Hepatol 2001;34:584-6.
  • Niesters HGM, Honkoop P, Haagsma EB, deMan RA, Schalm SW, Osterhaus ADME. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998;177:1382-5.
  • Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD- motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-26.
  • Fu L, Cheng YC, Role of additional mutation outside the YMDD Motif of hepatitis B virus polymerase in L(-)Sddc(3TC) resistance. Biochem Pharmacol 1998;55:1567-72.
  • Kao JH, Chen PJ, Lai MY, Wang TH, Chen DS. Quasispecies of hepatitis C virus and genetic drift of the hypervatiabe region in chronic type C hepatitis. J Infect Dis 1995;172:261-4.
  • Lee CM, Bih FY, Chao YC, Govindarajan S, Lai MM. Evolution of hepatits delta virus RNA during chronic infection Virology 1992;188:265-73.
  • Saab S, Kim M, Wright TL, Han SHB, Martin P, Busuttil RW, Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000;119:1382-4.
  • Dodson SF, Bonham CA, Geller D, Fontes P, Balan V, Vargas H. The role of pre-transplant treatment with lamivudine in hepatitis B surface antigen positive patients undergoing liver transplantation [ Abstract]. Liver Transplant Surg 1999;5:C-6.
  • Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.
  • Fontana R, Lok ASF. Combination therapy for chronic hepatitis B. Hepatology 1997;26:234-7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.